8-K: Celularity Stockholders Elect Directors, Reject Equity Plan Boost

Celularity Inc. announced the results of its Annual Meeting, where stockholders elected Class I Directors, ratified its accounting firm, but rejected an amendment to increase shares for its equity incentive plan.

Summary

• Celularity Inc. held its Annual Meeting of Stockholders on December 19, 2025.
• Stockholders elected Peter Diamandis, M.D., Diane Parks, and Geoffrey Ling, M.D. to serve as Class I Directors until the 2028 annual meeting.
• The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified by stockholders.
• Stockholders did not approve the amendment to the Company's 2021 Equity Incentive Plan, which sought to increase the number of shares reserved for awards by 3,500,000 shares.

Sentiment

Score: 4

Explanation: Stockholders rejected a significant increase in shares for the equity incentive plan, indicating a lack of support for potential dilution or the proposed compensation structure, while other proposals passed as expected.

Positives

• Stockholders successfully elected the nominated Class I Directors to the Board.
• The appointment of EisnerAmper LLP as the independent registered public accounting firm for fiscal year 2025 was ratified, ensuring continuity in financial oversight.

Negatives

• Stockholders rejected the proposal to amend the 2021 Equity Incentive Plan to increase the number of shares available for awards by 3,500,000 shares, indicating a lack of support for potential dilution or the proposed compensation structure.

Future Outlook

NA

Industry Context

NA

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The rejection of the equity incentive plan amendment prevents potential dilution from that specific share increase, which may be viewed positively by existing shareholders. The election of directors impacts board composition and oversight.
• Employees: The rejection of the equity incentive plan amendment may impact future equity awards and compensation strategies for employees.

Next Steps

• Class I Directors Peter Diamandis, M.D., Diane Parks, and Geoffrey Ling, M.D. will hold office until the Company's annual meeting of stockholders in 2028.

Key Dates

Recommendation

Stockholders elected directors and ratified the auditor, which are standard governance actions. However, the rejection of the proposed increase in shares for the equity incentive plan indicates shareholder resistance to potential dilution, which could be viewed positively by existing shareholders concerned about share value, but negatively for management's ability to use equity for compensation. This creates a neutral to slightly cautious outlook, warranting a 'hold' as no fundamental business operations or financial performance changes are reported.

Keywords

Celularity, CELU, 8-K, Annual Meeting, Stockholder Vote, Board of Directors, Equity Incentive Plan, Auditor Ratification, Corporate Governance